Trial Profile

A phase 2a study of brilaroxazine in patients with major depressive disorder

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 09 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brilaroxazine (Primary)
Indications Major depressive disorder
Focus Therapeutic Use

Most Recent Events

04 Jan 2024 According to a Reviva Pharmaceuticals media release, the company is planning to initiate this study in 2024.
03 Apr 2023 New trial record
30 Mar 2023 According to a Reviva Pharmaceuticals media release, the company is planning to initiate this study in second half 2023, subject to the receipt of additional financing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com